Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 15/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762803 | 0.87 | OPRL1 (0.57) | EGLN1OPRL1OPRM1OPRK1PARP1 | |
| SCHEMBL13005817 | 0.82 | OPRL1 (0.60) | EGLN1OPRL1OPRM1OPRK1KDM4E | |
| SCHEMBL3773817 | 0.81 | EGLN1 (0.54) | EGLN1OPRL1OPRM1OPRK1 | |
| SCHEMBL3769763 | 0.80 | EGLN1 (0.48) | EGLN1OPRL1OPRM1OPRK1PARP1 | |
| SCHEMBL3763129 | 0.78 | OPRM1 (0.55) | OPRL1OPRM1OPRK1PARP1KDM4E | |
| SCHEMBL13005666 | 0.78 | KDM4E (0.42) | PARP1KDM4EALDH1A1 | |
| SCHEMBL3772162 | 0.78 | HRH3 (0.46) | EGLN1OPRL1OPRM1OPRK1 | |
| SCHEMBL3771973 | 0.77 | ALDH1A1 (0.46) | OPRL1OPRM1OPRK1PARP1KDM4E | |
| SCHEMBL4725264 | 0.76 | OPRL1 (0.49) | OPRL1OPRM1OPRK1KDM4EALDH1A1 | |
| SCHEMBL3769340 | 0.75 | KDM4E (0.49) | OPRL1OPRM1OPRK1PARP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | EGLN1 306/4885OPRL1 347/4885OPRM1 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.